Evaluation of SARS-CoV-2 Inhibitors

Famotidine was acquired from Sigma Aldrich (Missouri, USA; cat. No. F6889). Compound 6, a previously reported inhibitor of SARS-CoV-2 PL^pro function^{21 (link)} was acquired from MedChem Express, Inc. (New Jersey, USA; cat no. HY-17542). ML188, a compound with known 3CL^pro inhibitory activity¹⁵ was also acquired from MedChem Express, Inc. (cat. no HY-136259). Similarly, remdesivir. (cat. No HY-104077) an inhibitor of SARS-CoV-2 replication^{2 (link)} was purchased from the same vendor. All compounds were dissolved in 100% DMSO at 100 mM.

Free full text: Click here

Loffredo M., Lucero H., Chen D.Y., O’Connell A., Bergqvist S., Munawar A., Bandara A., De Graef S., Weeks S.D., Douam F., Saeed M, & Munawar A.H. (2021). The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication. Scientific Reports, 11, 5433.

Publication 2021

Famotidine ML188

A compound Dmso Famotidine Inhibitory Ml188 Remdesivir Sars cov 2

Top 5 similar protocols

Variable analysis

independent variables

Famotidine
Compound 6
ML188
Remdesivir

dependent variables

Not explicitly mentioned

control variables

All compounds were dissolved in 100% DMSO at 100 mM

controls

Positive control: Compound 6, a previously reported inhibitor of SARS-CoV-2 PLpro function
Positive control: ML188, a compound with known 3CLpro inhibitory activity

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!